Literature DB >> 23543219

Insulin-like growth factor-binding protein-7 (IGFBP7) transcript: A-to-I editing events in normal and cancerous human keratinocytes.

Malka Hochberg1, Leon Gilead, Gal Markel, Yael Nemlich, Yulia Feiler, Claes David Enk, Polina Denichenko, Rotem Karni, Arieh Ingber.   

Abstract

Non-melanoma skin cancers (NMSC) are the most common malignancies in caucasians worldwide. Insulin-like growth factor-binding protein-7 (IGFBP7) was suggested to function as a tumor suppressor gene in several cancers, and to play a role in the proliferation of keratinocytes. A-to-I RNA editing is a post-transcriptional mechanism frequently used to expand and diversify transcriptome and proteome repertoire in eukaryotic cells. A-to-I RNA editing can alter codons, substitute amino acids and affect protein sequence, structure, and function. Two editing sites were identified within the IGFBP7 transcript. To evaluate the expression and editing of IGFBP7 mRNA in NMSC compared to normal epidermis. We examined the expression and mRNA editing level of IGFBP7 in 22 basal cell carcinoma (BCC), 15 squamous cell carcinoma (SCC), and 18 normal epidermis samples that were surgically removed from patients by the Mohs Micrographic Surgery procedure. We studied the effect of IGFBP7 editing on an immortalized HaCaT keratinocyte cell model. IGFBP7 mRNA is over expressed in BCC and SCC compared to normal epidermis. Moreover, the IGFBP7 transcript is highly edited in normal epidermis, but its editing is significantly reduced in BCC and SCC. The edited form of IGFBP7 can inhibit proliferation and induce senescence in cultured keratinocytes. This study describes for the first time A-to-I editing in the coding sequence of a tumor suppressor gene in humans, and suggests that IGFBP7 editing serves as a fine-tuning mechanism to maintain the equilibrium between proliferation and senescence in normal skin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543219     DOI: 10.1007/s00403-013-1338-5

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  6 in total

1.  Fibroblasts potentiate melanoma cells in vitro invasiveness induced by UV-irradiated keratinocytes.

Authors:  Njainday Pulo Jobe; Veronika Živicová; Alžběta Mifková; Daniel Rösel; Barbora Dvořánková; Ondřej Kodet; Hynek Strnad; Michal Kolář; Aleksi Šedo; Karel Smetana; Karolina Strnadová; Jan Brábek; Lukáš Lacina
Journal:  Histochem Cell Biol       Date:  2018-02-12       Impact factor: 4.304

2.  Altered RNA editing in 3' UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors.

Authors:  Liye Zhang; Chih-Sheng Yang; Xaralabos Varelas; Stefano Monti
Journal:  Sci Rep       Date:  2016-03-16       Impact factor: 4.379

3.  Decreased A-to-I RNA editing as a source of keratinocytes' dsRNA in psoriasis.

Authors:  Lea Shallev; Eli Kopel; Ariel Feiglin; Gil S Leichner; Dror Avni; Yechezkel Sidi; Eli Eisenberg; Aviv Barzilai; Erez Y Levanon; Shoshana Greenberger
Journal:  RNA       Date:  2018-03-28       Impact factor: 4.942

Review 4.  Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma.

Authors:  Xing-Xing Huo; Shu-Jie Wang; Hang Song; Ming-de Li; Hua Yu; Meng Wang; Hong-Xiao Gong; Xiao-Ting Qiu; Yong-Fu Zhu; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

5.  Development and Validation of a Four Adenosine-to-Inosine RNA Editing Site-Relevant Prognostic Signature for Assessing Survival in Breast Cancer Patients.

Authors:  Jian Wan; Shizhen Chen; Anqin Zhang; Yiting Liu; Yangyang Zhang; Qinghua Li; Ziqi Yu; Yuwei Wan; Lei Yang; Qi Wang
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

6.  SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome.

Authors:  Sanaa Eddiry; Gwenaelle Diene; Catherine Molinas; Juliette Salles; Françoise Conte Auriol; Isabelle Gennero; Eric Bieth; Boris V Skryabin; Timofey S Rozhdestvensky; Lisa C Burnett; Rudolph L Leibel; Maithé Tauber; Jean Pierre Salles
Journal:  Genet Med       Date:  2021-05-26       Impact factor: 8.822

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.